Enhanced oral absorption of 20(S)-protopanaxadiol by self-assembled liquid crystalline nanoparticles containing piperine: In vitro and in vivo studies

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 641-652

  Jin, Xin ^a,b   Zhang, Zhen Hai ^a   Sun, E ^a   Tan, Xiao Bin ^a   Li, Song Lin ^c   Cheng, Xu Dong ^d   You, Ming ^d   Jia, Xiao Bin ^a  

^a KEY LABORATORY OF NEW DRUG DELIVERY SYSTEM OF CHINESE MATERIA MEDICA   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c Jiangsu Province Academy of Traditional Chinese Medicine   (China)

^d ALG Bioscience Co Ltd   (China)

Author keywords

20(S) protopanaxadiol; Bioavailability; Caco 2 cell monolayer; Cubosome; Metabolites; Piperine

Indexed keywords

CYTOCHROME P450; GLYCEROL OLEATE; NANOPARTICLE; PIPERINE; POLOXAMER; PROTOPANAXADIOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RELEASE; DRUG STRUCTURE; ENCAPSULATION; FRAGMENTATION REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CRYSTAL; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOLAYER CULTURE; NONHUMAN; PARTICLE SIZE; RAT; TIME OF FLIGHT MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ZETA POTENTIAL;

20(S)-PROTOPANAXADIOL; BIOAVAILABILITY; CACO-2 CELL MONOLAYER; CUBOSOME; METABOLITES; PIPERINE;

ABSORPTION; ADMINISTRATION, ORAL; ALKALOIDS; ANIMALS; AREA UNDER CURVE; BENZODIOXOLES; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; HUMANS; MALE; NANOPARTICLES; PARTICLE SIZE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; SAPOGENINS;

EID: 84873947933     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S38203     Document Type: Article

References (54)

1. Bae EA, Han MJ, Kim EJ, Kim DH. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch Pharm Res. 2004;27(1):61-67.
2. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos. 2003;31(8):1065-1071.
3. Xie HT, Wang GJ, Sun JG, et al. High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;818(2):167-173.
4. Dong H, Bai LP, Wong VK, et al. The in vitro structure-related anti-cancer activity of ginsenosides and their derivatives. Molecules. 2011;16(12):10619-10630.
5. Li G, Wang Z, Sun Y, Liu K, Wang Z. Ginsenoside 20(S)-protopanaxadiol inhibits the proliferation and invasion of human fibrosarcoma HT1080 cells. Basic Clin Pharmacol Toxicol. 2006;98(6):588-592.
6. Liu GY, Bu X, Yan H, Jia WW. 20S-protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and -independent pathways. J Nat Prod. 2007;70(2):259-264.
7. Zhu GY, Li YW, Tse AK, et al. 20(S)-Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells. Eur J Pharmacol. 2011;668(1-2):88-98.
8. Popovich DG, Kitts DD. Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch Biochem Biophys. 2002;406(1): 1-8.
9. Usami Y, Liu YN, Lin AS, et al. 20(S)-protopanaxadiol and 20(S)-protopanaxatriol as antiangiogenic agents and total assignment of 1H NMR spectra. J Nat Prod. 2008;71(3):478-481.
10. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol. 2007;59(5):589-601.
11. Yu Y, Zhou O, Hang Y, Bu X, Jia W. Antiestrogenic effect of 20S-protopanax-adiol and its synergy with tamoxifen on breast cancer cells. Cancer. 2007;109(11):2374-2382.
12. Li L, Chen X, Li D, Zhong D. Identification of 20(S)-protopanaxadiol metabolites in human liver microsomes and human hepatocytes. Drug Metab Dispos. 2011;39(3):472-483.
13. Han MH, Chen J, Chen S, Wang X. Development of a UPLC-ESI-MS/MS assay for 20(S)-Protopanaxadiol and pharmacokinetic application of its two formulations in rats. Anal Sci. 2010;26(7):749-753.
14. de Waard H, De Beer T, Hinrichs WL, Vervaet C, Remon JP, Frijlink HW. Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: elucidation of the mechanism by in-line raman spectroscopy. APPS J. 2010;12(4):569-575.
15. Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine. 2010;5:13-23.
16. Garg G, Saraf S, Saraf S. Cubosomes: an overview. Biol Pharm Bull. 2007;30(2):350-353.
17. Guo C, Wang J, Cao F, Lee RJ, Zhai G. Lyotropic liquid crystal systems in drug delivery. Drug Discov Today. 2010;15(23-24):1032-1040.
18. Zeng N, Gao X, Hu Q, et al. Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption. Int J Nanomed. 2012;7:3703-3718.
19. Siekmann B, Bunjes H, Koch MH, Westesen K. Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride-water phases. Int J Pharm. 2002;244(1-2):33-43.
20. Esposito E, Eblovi N, Rasi S, et al. Lipid-based supramolecular systems for topical application: a preformulatory study. AAPS Pharm Sci. 2003;5(4):E30.
21. Vellaichamy L, Balakrishnan S, Panjamurthy K, Manoharan S, Alias LM. Chemopreventive potential of piperine in 7,12-dimethylbenz[a]anthracene-induced skin carcinogenesis in Swiss albino mice. Environ Toxicol Pharmacol. 2009;28(1):11-18.
22. Pradeep CR, Kuttan G. Piperine is a potent inhibitor of nuclear factor-kappaB (NF-kappaB), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells. Int Immunopharmacol. 2004;4(14):1795-1803.
23. Hwang YP, Yun HJ, Kim HG, et al. Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by piperine via the inhibition of PKCα/ERK1/2-dependent matrix metalloproteinase-9 expression. Toxicol Lett. 2011;203(1):9-19.
24. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002;302(2): 645-650.
25. Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase,andsulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos. 2008;36(8):1594-1605.
26. Caro I, Boulenc X, Rousset M, et al. Characterisation of a newly isolated Caco-2 clone (TC-7), as a model of transport processes and biotransformation of drugs. Int J Pharm. 1995;116(2):147-158.
27. Chen J, Lin H, Hu M. Metabolism of flavonoids via entericrecycling: role of intestinal disposition. J Pharmacol Exp Ther. 2003;304(3):1228-1235.
28. Jia XB, Chen J, Lin H, Hu M. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther. 2004;310(3):1103-1113.
29. Lv LZ, Tong CQ, Lv Q, et al. Enhanced absorption of hydroxysafflor yellow A using a self-double-emulsifying drug delivery system: in vitro and in vivo studies. Int J Nanomedicine. 2012;7:4099-4107.
30. Guan M, Zhu QL, Liu Y, et al. Uptake and transport of a novel anticancer drug-delivery system: lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers. Int J Nanomedicine. 2012;7:1921-1930.
31. Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm. 2010;396:179-187.
32. Coyuco JC, Liu Y, Tan BJ, Chiu GN. Functionalized carbon nanomaterials: exploring the interactions with Caco-2 cells for potential oral drug delivery. Int J Nanomedicine. 2011;6:2253-2263.
33. Wahlang B, Pawar YB, Bansal AK. Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. Eur J Pharm Biopharm. 2011;77(2):275-282.
34. Nguyen TH, Hanley T, Porter CJ, Boyd BJ. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. J Control Release. 2011;153(2):180-186.
35. Boyd BJ, Khoo SM, Whittaker DV, Davey G, Porter CJ. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. Int J Pharm. 2007;340(1-2):52-60.
36. Gustafsson J, Ljusberg-Wahren H, Almgren M, Larsson K. Submicron particles of reversed lipid phases in water stabilized by a nonionic amphiphilic polymer. Langmuir. 1997;13(26):6964-6971.
37. Lenhardt T, Vergnault G, Grenier P, Scherer D, Langguth P. Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: in vitro transport studies across intestinal epithelial monolayers. APPS J. 2008;10(3):435-438.
38. Thomson AB, Schoeller C, Keelan M, Smith L, Clandinin MT. Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can J Physiol Pharmacol. 1993;71(8):531-555.
39. Katneni K, Charman SA, Porter CJ. An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity. J Pharm Pharmacol. 2008;60(10):1311-1319.
40. Korjamo T, Heikkinen AT, Mönkkönen J. Analysis of unstirred water layer in in vitro permeability experiments. J Pharm Sci. 2009;98(12): 4469-4479.
41. Angelov B, Angelova A, Papahadjopoulos-Sternberg B, et al. Detailed structure of diamond-type lipid cubic nanoparticles. J Am Chem Soc. 2006;128(17):5813-5817.
42. Angelova A, Angelov B, Papahadjopoulos-Sternberg B, Ollivon M, Bourgaux C. Proteocubosomes: nanoporous vehicles with tertiary organized fluid interfaces. Langmuir. 2005;21(9):4138-4143.
43. Angelov B, Angelova A, Papahadjopoulos-Sternberg B, Hoffmann SV, Nicolas V, Lesieur S. Protein-containing PEGylated cubosomic particles: Freeze-fracture electron microscopy and synchrotron radiation circular dichroism study. J Phys Chem B. 2012;116(26):7676-7686.
44. Angelov B, Angelova A, Mutafchieva R, et al. SAXS investigation of a cubic to a sponge (L3) phase transition in self-assembled lipid nanocarriers. Phys Chem Chem Phys. 2011;13(8):3073-3081.
45. Angelova A, Angelov B, Mutafchieva R, Lesieur S, Couvreur P. Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery. Acc Chem Res. 2011;44(2):147-156.
46. Reen RK, Singh J. In vitro and in vivo inhibition of pulmonary cytochrome P450 activities by piperine, a major ingredient of piper species. Indian J Exp Biol. 1991;29(6):568-573.
47. Kong HW, Wang M, Venema K, et al. Bioconversion of red ginseng saponins in the gastro-intestinal tract in vitro model studied by high-performance liquid chromatography-high resolution Fourier transform ion cyclotron resonance mass spectrometry. J Chromatogr A. 2009; 1216(11):2195-2203.
48. Lee J, Lee E, Kim D, Lee J, Yoo J, Koh B. Studies on absorption, distribution and metabolism of ginseng in humans after oral administration. J Ethnopharmacol. 2009;122(1):143-148.
49. Lee JE, Lee S, Sung J, Ko G. Analysis of human and animal fecal microbiota for microbial source tracking. ISME J. 2011;5(2):362-365.
50. Winter J, Moore LH, Dowell VR Jr, Bokkenheuser VD. C-ring cleavage of flavonoids by human intestinal bacteria. Appl Environ Microbiol. 1989;55(5):1203-1208.
51. Jang IS, Kim DH. Purification and characterization of alpha-l-rhamnosidase from Bacteroides JY-6, a human intestinal bacterium. Biol Pharm Bull. 1996;19(12):1546-1549.
52. Kim DH, Kim SY, Park SY, Han MJ. Metabolism of quercetin by human intestinal bacteria and its relation to some biological activities. Biol Pharm Bull. 1999;22(7):749-751.
53. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos. 2003;31(8):1065-1071.
54. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci. 2004;95(2):153-157.